Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 31

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 31
---
 age-related conditions and certain cancers. We believe Telomir-1
has the potential to protect cells in situ by mitigating metal overload, particularly of iron and copper, which are known to accelerate
oxidative stress and contribute to telomere attrition. By modulating ion levels and reducing oxidative damage, Telomir-1 may help preserve
telomere integrity, restore cellular homeostasis, and enhance overall cell resilience, potentially slowing down age-related degeneration.
Additionally, by reversing oxidative stress, Telomir-1 may help mitigate the severity of viral infections such as bird flu by strengthening
cellular defense mechanisms and improving immune system function, potentially reducing disease progression and severity.

Basis
of presentation

The
accompanying unaudited condensed financial statements include the accounts of the Company and have been prepared in accordance with accounting
principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions to Quarterly
Report on Form 10-Q, and Regulation S-X. These financial statements do not include all information and notes required by GAAP for
annual financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the
notes to the financial statements included in the Company’s Form 10-K for the year ended December 31, 2024. In the opinion
of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation of interim financial
information, have been included. Operating results for the periods presented are not necessarily indicative of expected results for the
full year. Additionally, certain prior period amounts have been reclassified to conform to current period presentation in accompanying
unaudited condensed consolidated financial statements.

Research
and development expense

Research
and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties, such as contract
research organizations and consultants, who conduct research and development activities on behalf of the Company.

Use
of estimates

The
preparation of financial statements in accordance with generally accepted accounting principles in the United States of America requires
the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. Actual results may differ from such estimates and such differences could be material. Significant estimates during
the reporting periods include stock-based compensation and the deferred tax asset